6 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 6 of 6 clinical reviews.
Ezetimibe is FDA-approved for primary hyperlipidemia but used off-label as adjunctive therapy in familial hypercholesterolemia. Learn evidence-based dosing, clinical trial data, and guideline recommendations.
A clinical evidence summary of ezetimibe (Zetia) use in familial hypercholesterolemia, covering FDA indications, key trials like IMPROVE-IT and ENHANCE, pediatric data, and guideline recommendations from the AHA/ACC and ESC/EAS.
A guide to using ezetimibe (Zetia) in familial hypercholesterolemia, covering FDA-approved indications, LDL-lowering data from IMPROVE-IT and SHARP, combination strategies with statins and PCSK9 inhibitors, and risk-benefit tradeoffs for HeFH and HoFH.
Ezetimibe is FDA-approved as adjunctive therapy for primary hyperlipidemia and HoFH but is used off-label in broader FH management. Learn the evidence, monitoring protocols, and clinical guidance.
Does ezetimibe (Zetia) prevent stroke? A detailed review of IMPROVE-IT, FOURIER secondary analyses, guideline positions, and the off-label evidence for using ezetimibe in stroke prevention.
Ezetimibe (Zetia) is not FDA-approved for stroke prevention, but LDL-lowering data from IMPROVE-IT and other trials suggest a possible role. Review the evidence, risks, and when clinicians consider it off-label.